Alkermes PLC
Gesloten
SectorGezondheidszorg
45.82 -0.54
Overzicht
Wijziging aandelenprijs
24u
Min
45.62
Max
46
Inkomsten | 67M 501K |
|---|---|
Verkoop | 103M 496M |
K/W Sectorgemiddelde | 121.316 56.597 |
EPS | 0.52 |
Winstmarge | 0.101 |
Werknemers | 2,050 |
EBITDA | 76M 54M |
Volgende Winsten | 27 okt 2026 |
|---|
Marktkapitalisatie | -1.1B 7.7B |
|---|---|
Vorige openingsprijs | 46.36 |
Vorige sluitingsprijs | 45.82 |
Nieuwssentiment
By Acuity
50%
50%
126 / 339 Rangschikking in Healthcare
Alkermes PLC Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Alkermes PLC Prognose
Sentiment
By Acuity
126 / 339 Rangschikking in Gezondheidszorg
Nieuwssentiment
Neutral
Volatiliteit
Onder gemiddelde
Nieuws Volume (RCV)
Onder gemiddelde
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.